Last reviewed · How we verify

NCT04856878: VanCat

Effect of Vancomycin After Catheter Replacement

Status unknown Phase 4 Last updated 29 April 2021
What this trial tests

Phase 4 trial testing Vancomycin in Central Line-associated Bloodstream Infection (CLABSI) in 100 participants. Status unknown.

Timeline
1 June 2021
Primary endpoint
30 June 2024
31 December 2024

Quick facts

Lead sponsorUniversity of Zurich
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 June 2021
Primary completion30 June 2024
Estimated completion31 December 2024

Drugs / interventions tested

Conditions studied

Sponsor

University of Zurich

Who can join

18 and older, any sex, with Central Line-associated Bloodstream Infection (CLABSI) or Catheter-related Bloodstream Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized controlled trial of the effect of a single-dose intravenous Vancomycin after catheter replacement for suspected central line-associated bloodstream infection on resolution of infection in critically ill patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Vancomycin

Trials testing the same drug.

Other recruiting trials for Central Line-associated Bloodstream Infection (CLABSI)

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04856878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing